AL amyloidosis is a severe, untreatable disease related to multiorgan infiltration by b-fibrils derived from monoclonal immunoglobulin light chain (LC) (1) . Cardiac involvement carries a very poor prognosis. 1 We report an 18-month follow-up of a 45-year woman who successfully underwent both a cardiac and an unrelated bone marrow transplantation (BMT).
Symptoms of restrictive cardiomyopathy led to a biopsy proven diagnosis of AL amyloidosis in May 1999. At diagnosis, there was no evidence of other organ dysfunction. There was no detectable monoclonal Ig in the serum, but moderate proteinuria (0.3g/24 h) consisting mainly (70%) of a monoclonal kappa LC (uKLC). Only 2% 110  90  85  95  105  115  100  110   70  76  68  74  64  77  73  72   10  10  10  11  11  10  10.5  11   2  4  6  8  10  12  14  16  18 plasma cells were identified in the bone marrow (BM), confirming the diagnosis of primary amyloidosis. After initial improvement following high-dose melphalan and autologous stem cell transplantation in July 1999, she developed congestive heart failure and cardiac arrest. She underwent orthotopic heart transplantation in July 2001 in association with quadruple immunosuppressive therapy (ATG 10 mg/kg, Tacrolimus, MMF, methylprednisolone). The postoperative course was uneventful.
After 6 months, we performed an unrelated HLAidentical BMT in order to eradicate the underlying disease responsible for the KLC production. At that time, the disease had progressed to stage I multiple myeloma with 16% plasma cells in the BM, 69% of which demonstrated a 13q14 deletion by FISH. She received a conditioning regimen combining busulfan and cyclophosphamide, and continued with immunosuppression (tacrolimus, MMF and prednisone) as prophylaxis against graft-versus-host disease (GVHD). Cardiac rejection was prevented by a second course of antithymoglobulin globulin (2.5 mg/kg/day at day 1 and day 2 post-BMT). Follow-up was satisfactory since no GVHD, infection, or cardiac rejection occurred as assessed by sequential endomyocardiac biopsies (Figure 1 ). Since Bence Jones proteinuria was undetectable, KLC production was further monitored in the serum using a highly sensitive immunonephelometric assay (FreeliteTM) and showed a regular decline (Figure 1) .
At 12 months following BMT, her clinical and cardiac condition was satisfactory. The uKLC was undetectable by classical immunofixation. Chimerism was 100% donor type. Cytological and cytogenetic analyses showed a normal BM and the initial B cell clone was undetectable by PCR in the BM aspirate. However, the KLC level was noted to increase ( Figure 1) . Concomitantly, the M12 cardiac biopsy showed no signs of rejection but, for the first time, a slight reappearance of amyloid deposits. Therefore, we decided in favor of a graft-versus-myeloma (GVM) effect by decreasing the prednisone dose from 15 to 10 mg/ day. This was beneficial since the level of KLC was seen to decrease ( Figure 1) . No clinical symptoms of GVHD or cardiac rejection were noted.
At month 18, her Karnovsky score is 90%, and her cardiac evaluation shows no sign of cardiomyopathy (Figure 1) . AL amyloidosis is an infiltrative disorder characterized by an extracellular deposit of insoluble fibrillary immunoglobulin light chains, whose production results from a plasma cell dyscrasia. Prognosis is mainly dependent on cardiac involvement, with a 6 month median survival once symptoms develop. 2 Heart transplantation alone for amyloid heart disease is not recommended because of organ scarcity, poor postoperative outcome, 3 and the recurrence of amyloid deposition in the graft. 2 Clinical improvement is based on treatment of the plasma cell dyscrasia followed by a slow regression of amyloid deposits. Low-intensity chemotherapy has little effect in achieving this goal. Intensive chemotherapy followed by autologous stem cell support has been shown to offer transient benefit. Allogeneic BMT, which has the additional advantage of a tumor-free graft and a potential GVM effect, could be more effective. 4, 5 However, preexisting cardiac dysfunction exposes these patients to lethal complications after BMT, 6 justifying the rationale for offering cardiac followed by allogeneic BM transplantation. The strategy of a preliminary heart transplant has already been suggested for some patients with cardiac amyloidosis who meet the criteria for autologous peripheral blood stem cell transplantation, 7 in order to avoid lethal complications following the latter. 
